The Executive Officers of Zai Lab Limited , Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, announced that they have
The Executive Officers of Zai Lab Limited , Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, announced that they have
טי אדמונדסון וג’ונתן וונג, כולם הסכימו שהם לא מתכננים למכור אף אחת ממניות החברה שלהם לשארית שנת 2024. הם עשויים למכור חלק מהמניות רק אם יהיה צורך בכך בשל תוכניות
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inozyme Pharma (INZY – Research Report), Zai Lab (ZLAB – Research Report) and Idexx Laboratories (IDXX – Research Report).
Inozyme Pharma (INZY)
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma today and set a price target of $14.00. The company’s shares closed last Monday at $5.87.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $16.50, implying a 153.8% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Zai Lab (ZLAB)
Bank of America Securities analyst David Li reiterated a Buy rating on Zai Lab today and set a price target of $20.70. The company’s shares closed last Monday at $15.49, close to its 52-week low of $15.24.
According to TipRanks.com, Li is ranked #8631 out of 8796 analysts.
Zai Lab has an analyst consensus of Strong Buy, with a price target consensus of $49.90.
Idexx Laboratories (IDXX)
In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on Idexx Laboratories, with a price target of $600.00. The company’s shares closed last Monday at $514.70.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Currently, the analyst consensus on Idexx Laboratories is a Moderate Buy with an average price target of $621.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INZY:
Zai Lab Limited (ZLAB) partner Bristol Myers Squibb (BMY) announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI or adagrasib as a monotherapy in patients with pretreated locally advanced or
Zai Lab (ZLAB) said its partner Novocure (NVCR) announced the Phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for